Evolus (NASDAQ:EOLS) Trading Down 4.7% - What's Next?

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s share price dropped 4.7% during trading on Monday . The company traded as low as $9.59 and last traded at $9.57. Approximately 738,868 shares were traded during trading, a decline of 20% from the average daily volume of 929,089 shares. The stock had previously closed at $10.04.

Analyst Ratings Changes

EOLS has been the subject of a number of research reports. Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Evolus in a research report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. BTIG Research initiated coverage on Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective for the company. Finally, Barclays upped their price objective on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Evolus presently has a consensus rating of "Buy" and an average target price of $23.75.

Evolus Stock Down 0.6%

The company has a fifty day simple moving average of $10.30 and a 200-day simple moving average of $11.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market cap of $656.37 million, a P/E ratio of -11.19 and a beta of 1.00.

Insider Buying and Selling at Evolus

In other news, CFO Sandra Beaver sold 8,996 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $119,286.96. Following the completion of the transaction, the chief financial officer now owns 173,583 shares of the company's stock, valued at $2,301,710.58. This represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $60,147.36. Following the completion of the transaction, the chief marketing officer now directly owns 95,671 shares of the company's stock, valued at approximately $1,268,597.46. This trade represents a 4.53% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 73,353 shares of company stock valued at $881,251. Company insiders own 5.90% of the company's stock.

Hedge Funds Weigh In On Evolus

A number of hedge funds have recently made changes to their positions in EOLS. Nuveen LLC bought a new position in shares of Evolus in the first quarter worth about $12,330,000. Tri Locum Partners LP bought a new position in shares of Evolus in the fourth quarter worth about $8,198,000. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Evolus by 287.2% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock worth $7,753,000 after acquiring an additional 520,859 shares during the period. Caligan Partners LP boosted its stake in shares of Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after acquiring an additional 498,900 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new position in shares of Evolus in the first quarter worth about $5,851,000. Institutional investors own 90.69% of the company's stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.